Clinical Trials

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03313544 2023-04-21

Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1

Phase 4 Unknown

50 enrolled

Lung Neoplasms, Melanoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03134118 2023-02-21

NIVOTHYM

55 enrolled

Thymoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03542461 2022-10-03

EDEN

Phase 3 Unknown

125 enrolled

Squamous Non-small Cell Lung Cancer

NCT05468294 2022-07-21

Nivokin

3 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05265650 2022-07-19

Noelia

30 enrolled

Non-Small Cell Lung Cancer Metastatic

NCT04013334 2022-06-16

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Other solid neoplasmThoracic

12 enrolled

Mesothelioma, Malignant

NCT03808480 2022-04-06

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

22 enrolled

BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Phase 1 Unknown

219 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT05236608 2022-03-25

ADIVO Lung

53 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04521075 2021-08-16

A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC

42 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

400 enrolled

BreastDermatologicGenitourinaryThoracic

Lung Neoplasms, Melanoma

NCT04142931 2021-03-24

Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors

Phase 1 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Triple Negative Breast Neoplasms

NCT03048500 2020-10-14

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

17 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

130 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

30 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04331626 2020-04-02

Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

Phase 4 Unknown

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03823625 2020-03-25

SQUINT

112 enrolled

Squamous-Cell Lung Cancer

NCT04015778 2020-02-12

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04250246 2020-01-31

NIBIT-ML1

184 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04211896 2019-12-26

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04023617 2019-07-17

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

72 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02852083 2018-01-18

ModuLung

86 enrolled